Filing Details
- Accession Number:
- 0001209191-18-011252
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-02-20 16:05:38
- Reporting Period:
- 2018-02-15
- Accepted Time:
- 2018-02-20 16:05:38
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1488613 | Foundation Medicine Inc. | FMI | Services-Medical Laboratories (8071) | 271316416 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1585017 | Jason Ryan | 150 Second Street C/O Foundation Medicine, Inc. Cambridge MA 02141 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-02-15 | 15,000 | $29.63 | 64,230 | No | 4 | M | Direct | |
Common Stock | Disposition | 2018-02-15 | 15,000 | $67.53 | 49,230 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Common Stock (right to buy) | Disposition | 2018-02-15 | 15,000 | $0.00 | 15,000 | $29.63 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
7,147 | 2024-02-06 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2017.
- The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.55 to $68.85, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
- This option was granted on February 6, 2014 and vested in equal quarterly installments beginning on April 1, 2014 until fully vested on January 1, 2018.